References
- Flint R, Cardozo L, Grigoriadis T, Rantell A, Pitsouni E, Athanasiou S. Rationale and design for fractional microablative CO2 laser versus photothermal non-ablative erbium:YAG laser for the management of genitourinary syndrome of menopause: a non-inferiority, single-blind randomized controlled trial. Climacteric 2019;21:306–10
- North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902
- Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc 2017;92:1842–9
- Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause 2018;25:21–8
- Buttini MJ, Maher C. The first published randomised controlled trial of laser treatment for vaginal atrophy raises serious questions. Med J Aust 2018;209:376–7
- Federal Drug Administration. FDA Warns Against Use of Energy-Based Devices to Perform Vaginal 'Rejuvenation' or Vaginal Cosmetic Procedures: FDA Safety Communication. 2018. Available from: https://www.fda.gov/medicaldevices/safety/alertsandnotices/ucm615013.htm [last accessed 8 Dec 2018]
- O'Reilly B, The efficacy and safety of Fotona Smooth® Device for the treatment of stress urinary incontinence. 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03098992?recrs=ab&cond=Female+Stress+Incontinence&draw=2&rank=11 [last accessed 25 Feb 2019]